TY - JOUR T1 - Evaluation of the relationship between the metabolic status, the gastric emptying and the diabetic neuropathy JF - EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING Y1 - 2006 A1 - M Papos A1 - Tamás Várkonyi A1 - É Börcsök A1 - R Takács A1 - C Lengyel A1 - M Lázár A1 - P Kempler A1 - Eörs Máté A1 - J Lonovics A1 - László Pávics VL - 33 SN - 1619-7070 N1 - UT: 000202967400029SU: Suppl. 2 JO - EUR J NUCL MED MOL I ER - TY - JOUR T1 - Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. JF - JOURNAL OF AFFECTIVE DISORDERS Y1 - 2005 A1 - Miklós Árgyelán A1 - Zoltán Szabó A1 - Balázs Kanyó A1 - Attila Tanacs A1 - Zsuzsanna Kovács A1 - Zoltán Janka A1 - László Pávics AB - BACKGROUND: Bupropion is thought to exert its antidepressive effect by blocking the dopamine transporter (DAT). The purpose of this study was to evaluate the DAT activity in depressed patients by means of 99mTc-TRODAT-1 SPECT in relation to the efficacy of bupropion treatment. METHODS: In 12 healthy controls and 16 depressed patients the baseline DAT activity was examined. Nine of the 16 patients went through an additional second SPECT investigation, after 4 weeks of bupropion treatment. RESULTS: In the depressed patients, the baseline DAT striatum-occipital ratio (SOR) (1.04+/-.36, mean+/-SD) was not significantly different from that in the control group (1.12+/-.33) (p>.05). Correlation was found between baseline SOR and HAM-D score change (r=-.745, p=.02) of the bupropion treated patients. The average DAT occupancy due to the bupropion treatment was 20.84+/-27.7%. No significant correlation between the therapeutical effectiveness and the occupancy was observed. LIMITATIONS: One of the limiting factors of our study has been the lack of drug monitoring. CONCLUSIONS: In good agreement with other PET studies, we found 20.84% DAT occupancy during bupropion treatment. The lack of correlation between the efficacy of therapy and occupancy of DAT may raise the question as to whether other mechanisms are involved in the effect of bupropion. VL - 89 SN - 0165-0327 IS - 1-3 N1 - UT: 000234355500012ScopusID: 28444466222doi: 10.1016/j.jad.2005.08.016 JO - J AFFECT DISORDERS ER - TY - JOUR T1 - Effects of bupropion in depression: a 99mTc-TRODAT SPECT study JF - EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING Y1 - 2004 A1 - Miklós Árgyelán A1 - Zoltán Szabó A1 - Balázs Kanyó A1 - Attila Tanacs A1 - Zsuzsanna Kovács A1 - Zoltán Janka A1 - László Pávics VL - 31 SN - 1619-7070 N1 - UT: 000223419900123SU: Suppl. 2 JO - EUR J NUCL MED MOL I ER - TY - JOUR T1 - Evaluation of cerebral vasoreactivity by SPECT and transcranial Doppler sonography using the acetazolamide test. JF - NUKLEARMEDIZIN-NUCLEAR MEDICINE Y1 - 1994 A1 - László Pávics A1 - F Grünwald A1 - Pál Barzó A1 - Edit Ambrus A1 - C Menzel A1 - A Schomburg A1 - L Borda A1 - Eörs Máté A1 - Mihály Bodosi A1 - László Csernay A1 - H J Biersack AB - rCBF SPECT with 99mTc-HMPAO was performed prospectively in 29 patients (3 controls and 26 stroke patients) as well as TCD studies in 20 patients (3 controls and 17 stroke patients) before and after 1 g i.v. acetazolamide. The sensitivity of rCBF SPECT increased from 62% to 77% after acetazolamide provocation in stroke patients. In patients with a reversible neurological deficit, the sensitivity under resting conditions was 50% which increased to 71%, while in cases with a permanent deficit it increased from 75% to 83%. In the evaluation of the cerebrovascular reserve capacity the results of rCBF SPECT and TCD coincided in 91% of the hemispheres. The correlation was statistically significant. VL - 33 SN - 0029-5566 IS - 6 N1 - UT: A1994QA82500003ScopusID: 0028641548 JO - NUKLEARMED-NUCL MED ER - TY - JOUR T1 - REST AND STRESS (ACETAZOLAMIDE) RCBF SPECT AND TRANSCRANIAL DOPPLER SONOGRAPHY STUDIES IN CEREBROVASCULAR DISORDERS JF - EUROPEAN JOURNAL OF NUCLEAR MEDICINE Y1 - 1992 A1 - László Pávics A1 - Pál Barzó A1 - Eörs Máté A1 - Edit Ambrus A1 - Endre Katona A1 - Zita Morvay A1 - László Csernay VL - 19 SN - 0340-6997 IS - 8 N1 - UT: A1992JL49600094 JO - EUR J NUCL MED ER -